May 17, 2023
TB Alliance receives up to $3.9M from the Cystic Fibrosis Foundation to further the development of an NTM drug
TB Alliance will advance the research and development of a new compound that could be used to treat infections caused by nontuberculous mycobacteria
May 8, 2023
TB Alliance Statement on United Nations Multi-Stakeholder Hearing on Tuberculosis
Statement from Mel Spigelman, MD, President and CEO, TB Alliance
March 10, 2023
Ratan P. Watal Appointed to the Board of TB Alliance
Ratan Watal’s deep experience will accelerate new TB cures in India
March 8, 2023
TB and Women, on International Women’s Day 2023
February 23, 2023
TB Alliance Announces David Norton as Board Chair
February 23, 2023
Fireside Chat with Bruce Carter
A conversation with outgoing Chair of the TB Alliance Board of Directors
February 20, 2023
SimpliciTB Trial Results Presented at CROI 2023
Clinical Trial for Drug-Sensitive and Drug-Resistant TB Regimen Evaluated Shorter Regimens
February 3, 2023
Qurient Co. Ltd. and TB Alliance Announce Exclusive License Agreement for Telacebec (Q203), a New Anti-Tuberculosis Agent
Landmark Agreement for New Tuberculosis Treatment
December 19, 2022